CHINA'S NEW GENERATION OF BI-SPECIFIC ANTIBODIES:
A GAME CHANGER FOR SOLID TUMOURS
Bi-specific antibodies bind two different targets at once, letting one drug act through more than one pathway. China is one of the most active places in the world developing, testing and approving these therapies for solid tumours.
analyticsAt a Glance
- check_circleOne molecule targets two cancer-related pathways โ addressing resistance and immune suppression simultaneously.
- check_circleIvonescimab (PD-1/VEGF) and Cadonilimab (PD-1/CTLA-4) are NMPA-approved in China for lung and cervical/gastric cancer respectively.
- check_circleMany other bi-specific programmes remain investigational and are accessible through clinical trials.
- check_circleBiomarker testing โ NGS, PD-L1, MSI, HER2, CLDN18.2 โ is essential to identify the right candidate.
Main Bi-Specific Antibody Strategies in China
China has become one of the most active ecosystems for bi-specific antibody development. Several have received NMPA approval ahead of other markets; others are available through trials.
PD-1 / VEGF: Ivonescimab
Combines immune checkpoint blockade with anti-angiogenic effect. Approved in China for non-squamous NSCLC that has progressed after EGFR-targeted therapy, and as a first-line option for PD-L1-positive advanced NSCLC. Under study in further lung cancer settings and other tumour types.
PD-1 / CTLA-4: Cadonilimab
First PD-1/CTLA-4 bi-specific antibody approved in China โ initially for relapsed or metastatic cervical cancer after platinum-based chemotherapy, later for first-line gastric/GEJ cancer and first-line cervical cancer. Under study in other solid tumours.
Tumour-Targeted Bi-Specific Antibodies
Recognise two markers on the tumour itself โ improving selectivity and reducing harm to healthy tissue. Research explores combinations involving HER2, EGFR, CLDN18.2, B7-H3 and other targets. Most remain investigational.
T-Cell Engaging Bi-Specific Antibodies
Connect immune T cells directly to cancer cells via CD3. Strong activity in some blood cancers; harder in solid tumours due to variability and toxicity risk. China is developing next-generation designs aimed at improving safety and efficacy โ mostly trial-based.
Solid Tumours Where Bi-Specific Antibodies Are Most Studied
China's large trial network and domestic biotechnology have accelerated development across several cancer types. Suitability still requires individual biomarker review.
Lung Cancer (NSCLC)
A leading area โ particularly PD-1/VEGF strategies in non-squamous NSCLC after EGFR-targeted therapy or prior immunotherapy. Several approved and investigational options.
Gastric and GEJ Cancer
Explored through PD-1/CTLA-4, CLDN18.2-directed and HER2-directed approaches, supported by China's large trial experience in gastric and gastroesophageal junction cancer.
Cervical Cancer
An important area for immune-based bi-specific therapy in persistent, recurrent or metastatic disease after platinum-based chemotherapy.
Liver, Colorectal and Pancreatic
Hepatocellular carcinoma (dual immune + anti-angiogenic), microsatellite-stable colorectal (poor response to single-agent ICI) and pancreatic cancer (early immune recognition efforts) โ mostly investigational.
How CancerFax Helps
A structured case review to identify whether an approved bi-specific or a relevant trial is realistic โ not reliance on a single therapy or hospital name.
- 1
Report Collection and Case Understanding
Diagnosis, treatment history, current disease status and goals are reviewed to understand whether this category of therapy is realistic.
- 2
Biomarker and Report Interpretation
Pathology, NGS and biomarker reports are reviewed to see which approved or investigational bi-specific options may align with the tumour profile.
- 3
Hospital and Trial Matching
The case is mapped to suitable Chinese oncology centres and, where relevant, active clinical trials based on cancer type, biomarkers and prior treatment.
- 4
Second Opinion and Structured Review
Reports are shared with appropriate oncology teams for feedback on a realistic treatment pathway.
- 5
Cost, Timeline and Coordination
Guidance on likely pathway, estimated stay, required documents, cost range, travel considerations and post-treatment follow-up.
Frequently Asked Questions
Bi-Specific Antibodies in China
What is a bi-specific antibody in cancer treatment?
It is an engineered antibody that binds two different targets at the same time. In cancer this may let one medicine act through two pathways, such as activating the immune system while also blocking tumour blood vessel formation. The aim is to improve response or overcome resistance, though benefit depends on the individual case.
Why is China important for bi-specific antibody treatment?
China has a very active ecosystem for developing and testing these medicines, supported by a large trial network, experienced oncology centres and strong domestic biotechnology. In several cases regulatory approval there has come earlier than elsewhere. Access still depends on diagnosis, biomarkers, treatment history and hospital evaluation.
Can these therapies work after immunotherapy failure?
In some cases they may be considered after immunotherapy has stopped working, particularly when the drug targets an additional pathway such as VEGF or CTLA-4. This is not guaranteed and depends on cancer type, prior treatments and biomarker profile. An oncology team must review the full case first.
Which tests are needed before considering this treatment?
Depending on cancer type, an oncology team may need pathology and IHC review, imaging, and biomarker testing such as NGS, PD-L1, MSI/MMR, HER2, EGFR, ALK or CLDN18.2. Patients without some reports can still be reviewed, and missing tests can be identified during case preparation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Bi-Specific Antibody Options in China?
Share your pathology, biomarker reports and treatment history. Our clinical team will assess whether an approved bi-specific antibody or a relevant trial in China is a realistic option for your specific tumour type.
This information is for patient education and navigation support only. All treatment decisions must be made in consultation with a qualified oncologist.